Technavio, a tech-focused market research firm, has published a new report on the global human RSV drugs market, which is expected to experience a steady growth rate with a CAGR of more than 4% during the forecast period 2016-2020.
This latest report by Technavio covers the market outlook and growth prospects of the global human RSV drugs market for 2016-2020, considering 2015 as the base year. In addition, an overview of the market, key leading countries, vendor landscape, and a detailed analysis of the top vendors operating in this market are covered in the report.
Based on geographical division, Technavio market researchers segment the global human RSV drugs market into the following key regions: Europe, ROW, and the US.
Geographical segmentation of the global human RSV drugs market for 2015 (market share %)
|
ROW |
46.23% |
|
Europe |
28.51% |
|
US |
25.26% |
Source: Technavio
Human respiratory syncytial virus drugs market in ROW
In 2015, ROW accounted for the highest share of the global human RSV drugs market owing to the increasing occurrences of RSV infections in ROW, including the BRIC nations.
According to Sapna Jha, a lead analyst at Technavio, specializing in research on infectious and rare diseases, “The presence of a high-risk population, like infants below three months, is likely to add more revenue to the market during the forecast period. Besides this, the growing smoking population is expected to fuel the incidence rate of RSV infection in regions like Asia. Further, the people in low and middle-income regions, such as Africa, experience several trends such as crowded living conditions, exposure to indoor smoke pollution, and a family history of asthma or atopy which subsequently lead to RSV infections.”
The market in ROW is also observing high healthcare costs because of the rapidly surging instances of RSV infections. The growing burden of RSV infections in ROW has compelled vendors to focus on R&D activities to develop novel drugs. Several emerging vendors in the region are likely to bring novel therapies, such as oral drugs and vaccines, into the market during the forecast period.
Click here to request a free sample of this report
Human respiratory syncytial virus drugs market in Europe
The human respiratory syncytial virus drugs market in Europe is probable to benefit from the favorable regulatory conditions and the growing cases of hospitalization due to RSV infections in the region. In Europe, RSV leads to 42%-45% of hospital admissions for lower respiratory tract infections in children of ages below two years. At present, the guidelines and policies are supportive in Europe, where the usage of RSV drugs has not been restricted to any gender, class, or age. AstraZeneca’s Synagis has a strong position in Europe, as it is the only approved drug for RSV infections.
Human respiratory syncytial virus drugs market in the US
The growing occurrences of RSV infections in the US are expected to drive the market growth in the US during the forecast period. As per the research, RSV leads to approximately 57,500 hospitalizations among children of ages less than five years and every year, it leads to around 3 million infections in older adults. Moreover, the disease results in nearly 1 million medical interventions and 16,000 deaths each year in the US. The awaited approvals of new products, such as monoclonal antibodies and vaccines, over the forecast period is likely to boost the market growth in the US.
The top leading vendors operating in the global human RSV drugs market are:
- AstraZeneca
- AbbVie
- GSK
- Teva Pharmaceutical
Other prominent vendors in the market include Ablynx, ADMA Biologics, Alnylam Pharmaceuticals, Ark Biosciences, Aviragen Therapeutics, Bavarian Nordic, Boehringer Ingelheim, Gilead Sciences, ImmunoVaccine Technologies, Johnson & Johnson, Kyowa Hakko Kirin, Medivir, Mucosis, Mymetics, Novavax, Regeneron Pharmaceuticals, ReViral, and Vaxart.
A more detailed analysis is available in the Technavio report titled, ‘Global Human RSV Drugs Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
To read more press releases- click here.
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
https://www.technavio.com/
